Typing of hereditary renal amyloidosis presenting with isolated glomerular amyloid deposition
Tóm tắt
The commonly used methods for amyloid typing include immunofluorescence or immunohistochemistry (IHC), which sometimes may come with diagnostic pitfalls. Mass spectrometry (MS)-based proteomics has been recognized as a reliable technique in amyloid typing. We reported two middle-aged patients who presented with proteinuria, hypertension and normal renal function, and both had a family history of renal diseases. The renal biopsies of both patients revealed renal amyloidosis with the similar pattern by massive exclusively glomerular amyloid deposition. The IHC was performed by using a panel of antibodies against the common types of systemic amyloidosis, and demonstrated co-deposition of fibrinogen Aα chain and apolipoprotein A-I in the glomerular amyloid deposits of each patient. Then the MS on amyloid deposits captured by laser microdissection (LMD/MS) and genetic study of gene mutations were investigated. The large spectra corresponding to ApoA-I in case 1, and fibrinogen Aα chain in case 2 were identified by LMD/MS respectively. Further analysis of genomic DNA mutations demonstrated a heterozygous mutation of p. Trp74Arg in ApoA-I in case 1, and a heterozygous mutation of p. Arg547GlyfsTer21 in fibrinogen Aα chain in case 2. The current study revealed that IHC was not reliable for accurate amyloid typing, and that MS-based proteomics and genetic analysis were essential for typing of hereditary amyloidosis.
Tài liệu tham khảo
Pepys MB. Amyloidosis. Annu Rev Med. 2006;57:223–41.
Larsen CP, Walker PD, Weiss DT, Solomon A. Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies. Kidney Int. 2010;77:816–9.
Benson MD, Liepnieks J, Uemichi T, Wheeler G, Correa R. Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain. Nat Genet. 1993;3:252–5.
Murphy CL, Wang S, Weaver K, Gertz MA, Weiss DT, Solomon A. Renal apolipoprotein A-I amyloidosis associated with a novel mutant Leu64Pro. Am J Kidney Dis. 2004;44:1103–9.
Benson MD, Liepnieks JJ, Yazaki M, et al. A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene. Genomics. 2001;72:272–7.
Pepys MB, Hawkins PN, Booth DR, et al. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature. 1993;362:553–7.
Obici L, Franceschini G, Calabresi L, et al. Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid. 2006;13:191–205.
Galant NJ, Westermark P, Higaki JN, Chakrabartty A. Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy. Clin Sci (Lond). 2017;131:395–409.
Małyszko J, Kozłowska K, Małyszko JS. Amyloidosis: a cancer-derived paraproteinemia and kidney involvement. Adv Med Sci. 2017;62:31–8.
Yazaki M, Yoshinaga T, Sekijima Y, Kametani F, Okumura N. Hereditary fibrinogen Aα-chain amyloidosis in Asia: clinical and molecular characteristics. Int J Mol Sci. 2018;19:320.
Tougaard BG, Pedersen KV, Krag SR, et al. A case report of hereditary apolipoprotein A-I amyloidosis associated with a novel APOA1 mutation and variable phenotype. Eur J Med Genet. 2016;59:474–7.
Satoskar AA, Burdge K, Cowden DJ, Nadasdy GM, Hebert LA, Nadasdy T. Typing of amyloidosis in renal biopsies: diagnostic pitfalls. Arch Pathol Lab Med. 2007;131:917–22.
Sethi S, Vrana JA, Thesis JD, et al. Laser microdissection and mass spectrometry based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int. 2012;82:226–34.
Linke RP, Oos R, Wiegel NM, Nathrath WB. Classification of amyloidosis: misdiagnosing by way of incomplete immunohistochemistry and how to prevent it. Acta Histochem. 2006;108:197–208.
Picken MM, Herrera GA. The burden of “sticky” amyloid: typing challenges. Arch Pathol Lab Med. 2007;131:850–1.
Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59.
Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346:1786–91.
Sethi S, Thesis JD, Leung N, et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol. 2010;5:2180–7.
Benson MD. Ostertag revisited: the inherited systemic amyloidosis without neuropathy. Amyloid. 2005;12:75–87.
Eriksson M, Schonland S, Yumlu S, et al. Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J Mol Diagn. 2009;11:257–62.
Yao Y, Wang SX, Zhang YK. Hereditary fibrinogen Aα-chain amyloidosis caused by the E526V mutation: a case report and literature review. Beijing Da Xue Bao Yi Xue Ban. 2014;46:802–4.
Andeen NK, Lam DY, de Boer IH, Nicosia RF. Renal ApoA-1 amyloidosis with Glu34Lys mutation and intra-amyloid lipid accumulation. J Am Soc Nephrol. 2014;25:2703–5.
Rowczenio D, Dogan A, Theis JD, et al. Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol. 2011;179:1978–87.
Gillmore JD, Lachmann HJ, Rowczenio D, et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen a alpha-chain amyloidosis. J Am Soc Nephrol. 2009;20:444–51.
Kang HG, Bybee A, Ha IS, et al. Hereditary amyloidosis in early childhood associated with a novel insertion-deletion (indel) in the fibrinogen Aalpha chain gene. Kidney Int. 2005;68:1994–8.
Gillmore JD, Booth DR, Rela M, et al. Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen alpha-chain variant in an English family. QJM. 2000;93:269–75.
Stangou AJ, Banner NR, Hendry BM, et al. Hereditary fibrinogen a alpha-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood. 2010;115:2998–3007.
Gillmore JD, Stangou AJ, Lachmann HJ, et al. Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am J Transplant. 2006;6:2342–7.